Lundbeck CEO expects foundation backing for large acquisitions

If Lundbeck is to stimulate growth, a large-scale acquisition may be one option, the CEO says, though she acknowledges risk must be considered.

Deborah Dunsire, CEO at Lundbeck | Photo: Gregers Tycho/ERH

Long-term goals are more important than short-term solutions at Lundbeck. After speaking with the CEO, Danish financial daily Børsen reports that if the company wants to grow, a larger acquisition would be a clear option, but in Lundbeck's case, risk is a big concern for the foundation that owns the firm.

"I think that the Lundbeck Foundation would support an acquisition like this if we presented an attractive case that is really a quantum leap for Lundbeck, but we also need to demonstrate that if things don't all go to plan, and the wind is against us, it won't derail the company," says CEO Deborah Dunsire.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs